Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(3):584–590. doi: 10.1054/bjoc.1999.0968

Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer

C Magdalena 1, F Dominguez 2, L Loidi 2, J L Puente 1
PMCID: PMC2363325  PMID: 10682670

Abstract

In a previous report we suggested that the estimation of prothymosin α (PTA) levels in primary breast tumours might be used to identify breast cancer patients at high risk for distant metastasis (Dominguez F et al (1993) Eur J Cancer29A: 893–897). Here the role of tumour PTA levels as predictor was investigated with respect to both disease-free survival (DFS) and survival. Tumours were obtained from a series of 210 consecutive female patients with ductal carcinoma who underwent surgery at the Hospital Xeral de Galicia (Santiago de Compostela, Spain). Characteristics including PTA tumour levels, number of positive axillary nodes, patient's age at surgery and tumour histological grade were significantly associated with DFS and survival, as determined by univariate analysis. Patients with tumours with low or moderate PTA levels demonstrated a statistically decreased rate of tumour recurrence and a statistically significant increased overall survival in comparison with those whose tumours had high PTA levels. Patient's relative risk of dying was 2.1 times greater for tumours with high PTA levels than for those tumours with low or moderate PTA levels. In conclusion, these data support the hypothesis that tumour high PTA levels is associated with a worse outcome. © 2000 Cancer Research Campaign

Keywords: thymosin alpha 1 radioimmunoassay, tumour proliferation marker, overall mortality

Full Text

The Full Text of this article is available as a PDF (87.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Celis J. E., Madsen P., Ryazanov A. G. Increased phosphorylation of elongation factor 2 during mitosis in transformed human amnion cells correlates with a decreased rate of protein synthesis. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4231–4235. doi: 10.1073/pnas.87.11.4231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Conteas C. N., Mutchnick M. G., Palmer K. C., Weller F. E., Luk G. D., Naylor P. H., Erdos M. R., Goldstein A. L., Panneerselvam C., Horecker B. L. Cellular levels of thymosin immunoreactive peptides are linked to proliferative events: evidence for a nuclear site of action. Proc Natl Acad Sci U S A. 1990 May;87(9):3269–3273. doi: 10.1073/pnas.87.9.3269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dominguez F., Magdalena C., Cancio E., Roson E., Paredes J., Loidi L., Zalvide J., Fraga M., Forteza J., Regueiro B. J. Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer. Eur J Cancer. 1993;29A(6):893–897. doi: 10.1016/s0959-8049(05)80433-2. [DOI] [PubMed] [Google Scholar]
  4. Díaz-Jullien C., Pérez-Estévez A., Covelo G., Freire M. Prothymosin alpha binds histones in vitro and shows activity in nucleosome assembly assay. Biochim Biophys Acta. 1996 Sep 5;1296(2):219–227. doi: 10.1016/0167-4838(96)00072-6. [DOI] [PubMed] [Google Scholar]
  5. Eilers M., Schirm S., Bishop J. M. The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J. 1991 Jan;10(1):133–141. doi: 10.1002/j.1460-2075.1991.tb07929.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eschenfeldt W. H., Berger S. L. The human prothymosin alpha gene is polymorphic and induced upon growth stimulation: evidence using a cloned cDNA. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9403–9407. doi: 10.1073/pnas.83.24.9403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fraga M., García-Caballero T., Domínguez F., Pérez-Becerra E., Beiras A., Forteza J. Immunohistochemical location of prothymosin alpha in regenerating human hepatocytes and hepatocellular carcinomas. Virchows Arch A Pathol Anat Histopathol. 1993;423(6):449–452. doi: 10.1007/BF01606534. [DOI] [PubMed] [Google Scholar]
  8. Freedman L. S., Edwards D. N., McConnell E. M., Downham D. Y. Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer. 1979 Jul;40(1):44–55. doi: 10.1038/bjc.1979.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gallego R., Rosón E., García-Caballero T., Fraga M., Forteza J., Domínguez F., Beiras A. Prothymosin alpha expression in lymph nodes and tonsils: an optical and ultrastructural study. Acta Anat (Basel) 1992;143(3):219–222. doi: 10.1159/000147251. [DOI] [PubMed] [Google Scholar]
  10. Garcia-Caballero T., Dominguez F., Roson E., Gallego R., Zalvide J., Forteza J., Beiras A. Distribution of prothymosin alpha in rat and human adrenal cortex. Anat Rec. 1994 May;239(1):88–94. doi: 10.1002/ar.1092390110. [DOI] [PubMed] [Google Scholar]
  11. Gomez-Marquez J., Rodríguez P. Prothymosin alpha is a chromatin-remodelling protein in mammalian cells. Biochem J. 1998 Jul 1;333(Pt 1):1–3. doi: 10.1042/bj3330001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Goodall G. J., Dominguez F., Horecker B. L. Molecular cloning of cDNA for human prothymosin alpha. Proc Natl Acad Sci U S A. 1986 Dec;83(23):8926–8928. doi: 10.1073/pnas.83.23.8926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gómez-Márquez J., Segade F., Dosil M., Pichel J. G., Bustelo X. R., Freire M. The expression of prothymosin alpha gene in T lymphocytes and leukemic lymphoid cells is tied to lymphocyte proliferation. J Biol Chem. 1989 May 25;264(15):8451–8454. [PubMed] [Google Scholar]
  14. Gómez-Márquez J., Segade F. Prothymosin alpha is a nuclear protein. FEBS Lett. 1988 Jan 4;226(2):217–219. doi: 10.1016/0014-5793(88)81425-x. [DOI] [PubMed] [Google Scholar]
  15. Haritos A. A., Goodall G. J., Horecker B. L. Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Proc Natl Acad Sci U S A. 1984 Feb;81(4):1008–1011. doi: 10.1073/pnas.81.4.1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Loidi L., García-Caballero T., Vidal A., Zalvide J., Gallego R., Domínguez F. Complex regulation of prothymosin alpha in mammary tumors arising arising in transgenic mice. Life Sci. 1999;64(23):2125–2133. doi: 10.1016/s0024-3205(99)00161-7. [DOI] [PubMed] [Google Scholar]
  17. Lu K. P., Means A. R. Regulation of the cell cycle by calcium and calmodulin. Endocr Rev. 1993 Feb;14(1):40–58. doi: 10.1210/edrv-14-1-40. [DOI] [PubMed] [Google Scholar]
  18. Mol P. C., Wang R. H., Batey D. W., Lee L. A., Dang C. V., Berger S. L. Do products of the myc proto-oncogene play a role in transcriptional regulation of the prothymosin alpha gene? Mol Cell Biol. 1995 Dec;15(12):6999–7009. doi: 10.1128/mcb.15.12.6999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Papamarcaki T., Tsolas O. Prothymosin alpha binds to histone H1 in vitro. FEBS Lett. 1994 May 23;345(1):71–75. doi: 10.1016/0014-5793(94)00439-0. [DOI] [PubMed] [Google Scholar]
  20. Powles T. J. Adjuvant therapy for early breast cancer: a time to refine. J Natl Cancer Inst. 1997 Nov 19;89(22):1652–1654. doi: 10.1093/jnci/89.22.1652. [DOI] [PubMed] [Google Scholar]
  21. Rodríguez P., Viñuela J. E., Alvarez-Fernández L., Buceta M., Vidal A., Domínguez F., Gómez-Márquez J. Overexpression of prothymosin alpha accelerates proliferation and retards differentiation in HL-60 cells. Biochem J. 1998 May 1;331(Pt 3):753–761. doi: 10.1042/bj3310753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rodríguez P., Viñuela J. E., Alvarez-Fernández L., Gómez-Márquez J. Prothymosin alpha antisense oligonucleotides induce apoptosis in HL-60 cells. Cell Death Differ. 1999 Jan;6(1):3–5. doi: 10.1038/sj.cdd.4400450. [DOI] [PubMed] [Google Scholar]
  23. Roson E., Gallego R., Garcia-Caballero T., Fraga M., Dominguez F., Beiras A. Evolution of prothymosin alpha and proliferating cell nuclear antigen (PCNA) immunoreactivity through the development of rat ovarian follicles. Histochem J. 1993 Jul;25(7):497–501. doi: 10.1007/BF00159285. [DOI] [PubMed] [Google Scholar]
  24. Roson E., Garcia-Caballero G., Heimer E. P., Felix A. M., Dominguez F. Cellular distribution of prothymosin alpha and parathymosin in rat thymus and spleen. J Histochem Cytochem. 1990 Dec;38(12):1889–1894. doi: 10.1177/38.12.2254650. [DOI] [PubMed] [Google Scholar]
  25. Rosón E., Gallego R., García-Caballero T., Heimer E. P., Felix A. M., Domínguez F. Prothymosin alpha expression is associated to cell division in rat testis. Histochemistry. 1990;94(6):597–599. doi: 10.1007/BF00271986. [DOI] [PubMed] [Google Scholar]
  26. Rudolph P., Alm P., Heidebrecht H. J., Bolte H., Ratjen V., Baldetorp B., Fernö M., Olsson H., Parwaresch R. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst. 1999 Feb 3;91(3):271–278. doi: 10.1093/jnci/91.3.271. [DOI] [PubMed] [Google Scholar]
  27. Ryazanov A. G. Ca2+/calmodulin-dependent phosphorylation of elongation factor 2. FEBS Lett. 1987 Apr 20;214(2):331–334. doi: 10.1016/0014-5793(87)80081-9. [DOI] [PubMed] [Google Scholar]
  28. Sburlati A. R., Manrow R. E., Berger S. L. Prothymosin alpha antisense oligomers inhibit myeloma cell division. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):253–257. doi: 10.1073/pnas.88.1.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sigurdsson H., Baldetorp B., Borg A., Dalberg M., Fernö M., Killander D., Olsson H. Indicators of prognosis in node-negative breast cancer. N Engl J Med. 1990 Apr 12;322(15):1045–1053. doi: 10.1056/NEJM199004123221505. [DOI] [PubMed] [Google Scholar]
  30. Tsitsilonis O. E., Bekris E., Voutsas I. F., Baxevanis C. N., Markopoulos C., Papadopoulou S. A., Kontzoglou K., Stoeva S., Gogas J., Voelter W. The prognostic value of alpha-thymosins in breast cancer. Anticancer Res. 1998 May-Jun;18(3A):1501–1508. [PubMed] [Google Scholar]
  31. Vareli K., Tsolas O., Frangou-Lazaridis M. Regulation of prothymosin alpha during the cell cycle. Eur J Biochem. 1996 Jun 15;238(3):799–806. doi: 10.1111/j.1432-1033.1996.0799w.x. [DOI] [PubMed] [Google Scholar]
  32. Vega F. V., Vidal A., Hellman U., Wernstedt C., Domínguez F. Prothymosin alpha stimulates Ca2+-dependent phosphorylation of elongation factor 2 in cellular extracts. J Biol Chem. 1998 Apr 24;273(17):10147–10152. doi: 10.1074/jbc.273.17.10147. [DOI] [PubMed] [Google Scholar]
  33. Witzig T. E., Ingle J. N., Cha S. S., Schaid D. J., Tabery R. L., Wold L. E., Grant C., Gonchoroff N. J., Katzmann J. A. DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancer. Cancer. 1994 Sep 15;74(6):1752–1761. doi: 10.1002/1097-0142(19940915)74:6<1752::aid-cncr2820740618>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  34. Zalvide J. B., Cancio E., Alvarez C. V., Regueiro B. J., Dominguez F. Prothymosin alpha mRNA levels are invariant throughout the cell cycle. J Biol Chem. 1992 Apr 25;267(12):8692–8695. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES